A sulfonimide derivative of bezafibrate as a dual inhibitor of cyclooxygenase-2 and PPARα
We have identified a highly selective COX-2 inhibitor with a unique scaffold. This inhibitor retains PPARα antagonism at the same concentration range. It has the potential to be effective in treating certain types of cancer, such as hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), where COX-2 and PPARα are overexpressed.
Authors
- Rosa Amoroso (ORCID: https://orcid.org/0000-0002-8282-8535)
- Carmen Cerchia (ORCID: https://orcid.org/0000-0002-6631-5000)
- Alessandra Ammazzalorso (ORCID: https://orcid.org/0000-0003-4369-1772)
- Annalisa Contursi
- Ulrika Hofling
- Stefania Tacconelli (ORCID: https://orcid.org/0000-0003-4907-1822)
- Paola Patrignani (ORCID: https://orcid.org/0000-0003-1419-2691)
- Antonio Lavecchia (ORCID: https://orcid.org/0000-0002-2181-8026)
- Sara Di Berardino
- Alessandra De Michele
Institutions
- University of Chieti-Pescara (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-11-26
- DOI
- https://doi.org/10.3389/fphar.2024.1488722
- Citations
- 1
- Primary Topic
- Inflammatory mediators and NSAID effects
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- Queen Mary University of London
- European Commission
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro